NexEos Bio was founded with a mission of developing novel technologies to identify and treat underlying inflammation in eosinophil-mediated diseases.
 
We bring a sense of urgency to all we do, knowing patients need better solutions to manage their debilitating diseases.
Illuminating eosinophil-driven inflammation for a brighter tomorrow.

Our lead program (NDX33-o) is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE).

We are passionate about our goal of helping patients to maintain a high quality of life and to slow the progression of eosinophil-related diseases.

Latest News: April 10, 2020

 

FDA Grants Orphan Drug Designation to NexEos Bio’s Investigational Radioimaging Agentas a Diagnostic for the Management of Eosinophilic Esophagitis

NEXEOS BIO White Logo 2020MAR16 F CMYK-0

© 2020 Copyright NexEos Bio. All rights reserved.